Table 1.
Demographics and Clinical Data at Baseline of the Study Population.
| n=100 | |
|---|---|
| Age (yr) | 67.5±1.2 |
| Number of male/female | 7/93 |
| Postmenopausal (%) | 86 (92.4) |
| Body mass index (kg/m2) | 20.8±0.32 |
| Prednisolone usage (%) | 68 (68.0) |
| Bone mineral density (g/cm2) | 0.76±0.10 |
| Past history of fracture (%) | 21 (21) |
| Diagnosis, no. (%) | |
| Rheumatoid arthritis | 51 (51) |
| Systemic lupus erythematosus | 14 (14) |
| Polymyalgia rheumatica | 11 (11) |
| Polymyositis/dermyositis | 5 (5) |
| Mixed connected tissue disease | 4 (4) |
| Sjögren’s syndrome | 4 (4) |
| Vasculitis syndrome | 4 (4) |
| Systemic scleroderma | 3 (3) |
| Others | 4 (4) |
| Pre-denosumab treatment, no. (%) | |
| Bisphosphonates | 60 (60) |
| Teriparatide | 10 (10) |
| Vitamin D | 8 (8) |
| Vitamin K | 3 (3) |
| SERM | 3 (3) |
| Bone turnover markers | |
| NTx (nmolBCE/L) | 16.4±0.6 |
| TRACP-5b (mU/dL) | 265.6±17.0 |
| P1NP (µg/L) | 33.5±3.0 |
| BAP (µg/L) | 13.6±1.1 |
| OC (ng/mL) | 7.1±0.5 |
SERM: selective estrogen receptor modulators, NTx: N-telopeptide crosslinked of type I collagen, TRACP-5b: tartrate-resistant acid phosphatase isoform 5b, P1NP: procollagen type I N-terminal peptide, BAP: bone alkaline phosphatase, OC: osteocalcin